Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

QRX003

Small molecule · Inhibitor · developed by Quoin Pharmaceuticals

Phase 2/3 Most advanced trial
QNRX Developer
3 Registered trials

What is QRX003?

QRX003 is a topical lotion containing a serine protease inhibitor at 2% or 4% active drug. It is studied in Netherton syndrome, a rare inherited skin disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Inhibitor
Therapy area
Dermatology
Developer
Quoin Pharmaceuticals (QNRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07538583 Phase 2/3 Netherton Syndrome Recruiting QNRX
NCT06953466 Phase 2/3 Netherton Syndrome Recruiting QNRX
NCT05521438 Phase 2/3 Netherton Syndrome Active not recruiting QNRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Netherton Syndrome

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the QNRX page.

Follow QNRX, the company behind QRX003

See QNRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QNRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.